Literature DB >> 26788792

How the innate immune system trains immunity: lessons from studying atopic dermatitis and cutaneous bacteria.

Yuliya Skabytska1,2, Susanne Kaesler1,2, Thomas Volz1, Tilo Biedermann1.   

Abstract

The skin is the largest organ at the interface between environment and host. It plays a major protective role against pathogens as physical barrier, as site of first recognition, and as orchestrator of consecutive immune responses. In this process, immunological crosstalk between skin-resident and immune cells is required, and fixed innate immune responses were previously believed to orchestrate adaptive immunity of B and T lymphocytes. Today, we understand that diverse qualities of immune responses to different microbes need to be regulated by also varying responses at the level of first microbe recognition through receptors of the innate immune system. Only fine-tuning of the innate immune system allows for the orchestration of immune responses to the microbiota in the absence of inflammation as well as to pathogens in the context of protective responses including inflammation. Understanding how innate immunity precisely adapts is also important for diseases such as atopic dermatitis (AD) with chronic inflammation. In this review, we present data on how the innate immune system actually fine-tunes its responses with special focus on the immunological consequences of cutaneous innate immune sensing through TLR2. These new insights are highly relevant for understanding microbiota-associated state of health, immune defense, and the pathogenesis underlying chronic cutaneous inflammation as seen in AD.
© 2016 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26788792     DOI: 10.1111/ddg.12843

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  2 in total

Review 1.  Does HIV Exploit the Inflammatory Milieu of the Male Genital Tract for Successful Infection?

Authors:  Rachel T Esra; Abraham J Olivier; Jo-Ann S Passmore; Heather B Jaspan; Rushil Harryparsad; Clive M Gray
Journal:  Front Immunol       Date:  2016-06-24       Impact factor: 7.561

2.  CYT387, a Novel JAK2 Inhibitor, Suppresses IL-13-Induced Epidermal Barrier Dysfunction Via miR-143 Targeting IL-13Rα1 and STAT3.

Authors:  Yan Zu; Xiao-Fei Chen; Qiang Li; Shu-Ting Zhang
Journal:  Biochem Genet       Date:  2020-11-15       Impact factor: 1.890

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.